Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENTAFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENTAFAIR.
AMIKACIN SULFATE vs GENTAFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic